Uniting tofight skin cancerand save lives
We are a community of over 1,500 professionals dedicated to reducing the incidence and impact of skin cancer in New Zealand
Aotearoa New Zealand Melanoma Clinical Guidelines
4th edition now available
Leading the fight against skin cancer
Skin Cancer NZ is the leading organisation for skin cancer professionals in New Zealand.
We are working towards a future with fewer skin cancers, and where every person - no matter who they are or where they live - receives the best possible care.
By shaping strategy, defining best practice, supporting professionals and advocating for change, we are driving a nationwide effort to improve outcomes and strengthen how skin cancers are prevented, detected and treated across New Zealand.
Join the Skin Cancer NZ Foundation Club
A unique opportunity to be part of Skin Cancer NZ’s journey from the beginning. With only 100 places available, a one-off contribution will secure your spot as a founding member and help build a strong foundation for long-term impact.
Become a member
Skin Cancer NZ brings together health professionals, health promoters, researchers, policy makers, and advocates who are committed to improving skin cancer prevention, early detection and care.
Membership is free and takes less than a minute to complete.
Latest news
26 August 2026
A systematic review found that digital visual aids, including smartphone apps and websites, can improve knowledge, attitudes and intentions around regular self-skin examination (SSE), with generally positive effects on health outcomes. Some studies also showed improved detection of malignant skin lesions, although barriers to use and integration with clinical care need to be addressed.26 August 2026
AI-assisted deep learning accurately quantified tumour-infiltrating lymphocytes (iTILs) in melanoma lymph node biopsies and was strongly associated with major pathological response and longer event-free survival. High iTIL levels combined with high tumour mutational burden (TMB) were particularly predictive, supporting the potential of AI-assisted iTIL scoring to help guide neoadjuvant treatment and future melanoma trials.24 August 2026
An international Phase 3 clinical trial of the personalised mRNA treatment intismeran, given alongside the immunotherapy pembrolizumab (Keytruda), has shown promising results in people with high-risk melanoma following surgery. The trial, involving more than 1,000 people across 26 countries including 45 New Zealanders, found that adding intismeran to pembrolizumab reduced the risk of melanoma returning and spreading to other parts of the body, compared with pembrolizumab alone.With thanks to our Founding Members
Supporting a future with better skin cancer outcomes for all New Zealanders.
Already a member?
Log in to update your details and access member content. Contact us if you need help.